Prof. Michel Sadelain and his team at Columbia University have identified a single protein that could unlock CAR T-cell therapy's potential against the solid tumors that have, until now, resisted this revolutionary treatment. The breakthrough centers on blocking NFIL3, a protein that causes immune cells to exhaust and lose their fighting power—and early evidence from animal models shows the approach could extend survival and dramatically improve cancer outcomes.
CAR T-cell therapy represents one of modern medicine's most elegant solutions: doctors extract a patient's own immune cells, genetically reprogram them to recognize and destroy cancer, and return them to the body as a personalized weapon against disease. The approach has already transformed treatment for certain blood cancers, but solid tumors—the kind that form in organs like the lung, breast, and pancreas—have remained stubbornly resistant. Now, an international research collaboration led by Sadelain and Prof. Judith Feucht of University Hospital Tübingen has uncovered why, and more importantly, how to fix it.
In a systematic screening of roughly 400 transcription factors—proteins that act as genetic switches, controlling which genes turn on and off inside cells—the researchers zeroed in on NFIL3 as a critical culprit. When CAR T cells are deployed against tumors, NFIL3 gradually causes them to become "exhausted," losing their ability to proliferate and sustain their antitumor activity. But when the researchers used CRISPR/Cas9 gene-editing technology to disable NFIL3 in these cells, something remarkable happened: the modified CAR T cells remained functional far longer, multiplied more effectively, and maintained stronger cancer-fighting power.
The results, published in Cancer Discovery and conducted across multiple mouse tumor models, showed that CAR T cells without NFIL3 fought tumors more aggressively and extended overall survival. "Switching off NFIL3 could be a decisive step toward significantly improving the long-term potency of CAR T cells," Feucht explained. Celina May, a co-first author of the study from Feucht's research group, emphasized the clinical stakes: "Our goal is to improve the effectiveness of CAR T cells in solid tumors as well. We expect this to open up new possibilities in the treatment of cancer patients."
What makes this finding particularly significant is its potential reach. Solid tumors account for the vast majority of cancers worldwide, and their resistance to CAR T therapy has been a major limitation in expanding this powerful approach. If these animal model results translate to humans, they could transform treatment options for cancers that have been notoriously difficult to treat.
Feucht's work exemplifies the "bench-to-bedside" principle—the direct translation of laboratory discoveries into clinical practice. As both a researcher within Germany's iFIT Cluster of Excellence in oncology and a practicing pediatric oncologist at University Hospital Tübingen, she bridges the gap between scientific innovation and patient care. The path from animal models to human clinical trials will require careful development, and researchers caution that wider application is still some time away. Yet the evidence from these early studies offers genuine cause for optimism that blocking NFIL3 may prove effective in people, opening doors for cancer patients who have run out of options.